Peritoneal Metastases, a Frontier for Progress. [Review]
Citation: Surgical Oncology Clinics of North America. 27(3):413-424, 2018 Jul.PMID: 29935680Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Neoplasms/pa [Pathology] | *Peritoneal Neoplasms/sc [Secondary] | Humans | PrognosisYear: 2018Local holdings: Available online through MWHC library: 2002 - present, Available in print through MWHC library: 1999 - January 2007ISSN:- 1055-3207
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 29935680 | Available | 29935680 |
Available online through MWHC library: 2002 - present, Available in print through MWHC library: 1999 - January 2007
Copyright (c) 2018 Elsevier Inc. All rights reserved.
The treatments for peritoneal metastases have evolved over 30 years. Now the concepts that guided clinicians are being tested in clinical trials to optimize standardized treatment regimens. The essential features of a successful management plan are cytoreductive surgery combined with cancer chemotherapy in a large volume of intraperitoneal fluid administered into the peritoneal space. The cytotoxicity of the cancer chemotherapy is maximized by moderate hyperthermia. The patients must be carefully selected using well-defined prognostic indicators. The efforts to date are multinational with centers of excellence located throughout the world.
English